The goal of this study is to develop SHP1 covalent inhibitors with the requisite potency, selectivity, tempered reactivity, and drug-like properties to interrogate the therapeutic potential of SHP1 as a cancer immunotherapy target. Here, PTPN6 is linked to cancer.